The C5a complement activation peptide increases IL-1β and IL-6 release from amyloid-β primed human monocytes: implications for Alzheimer’s disease

Inflammation. Basic principles and clinical correlates

Biomedicine & Pharmacotherapy · 1989 · 2.4K citations · Full text

Inflammation, Basic Principles, Immunology +3

Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

W. Sue T. Griffin, Laura Stanley, Lon R. White et al. · Proceedings of the National Academy of Sciences · 1989 · 1.8K citations · Full text

Immunology, Neurochemical Biomarkers, Glioma +22

Activation of microglial cells by β-amyloid protein and interferon-γ

Lucia Meda, Marco A. Cassatella, Györgyi I. Szendrei et al. · Nature · 1995 · 1.3K citations

Inflammation, Medicine, Brain-immune Interaction +6

Control of Cachectin (Tumor Necrosis Factor) Synthesis: Mechanisms of Endotoxin Resistance

Bruce Beutler, Nadia Krochin, Ian W. Milsark et al. · Science · 1986 · 1.3K citations

Complement activation by beta-amyloid in Alzheimer disease.

Jack T. Rogers, Neil R. Cooper, Scott D. Webster et al. · Proceedings of the National Academy of Sciences · 1992 · 809 citations

Immunology, Cell Death, Neurochemical Biomarkers +19